 |
|
Targeted Treatment of Active Trachoma—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Our prospective study examined the effect of azithromycin treatment on active trachoma and C trachomatis infection rates in an endemic area, with 2-year follow-up beyond the last treatment to determine risks of reemergence for both. We are aware of no similar studies despite documentation of reemergence 6 to 24 months following treatment.1 Dr Mabey and colleagues note 3 studies showing sustained infection reduction after mass treatment. However, 1 study found increasing infection prevalence from 2 to 12 months without further follow-up,2 another found infection reemergence in different villages from 2 to 24 months,3 and only 1 showed sustained reduction at 24 months.4
We used robust generalized estimating equation logistic and mixed effects models to perform longitudinal analysis of all individuals seen every 6 months to determine risk factors for reemergent infection. There were no differences among communes for active trachoma prevalence, demographics, ethnicity, socioeconomic status, or water access; . . . [Full Text of this Article]
Deborah Dean, MD, MPH
ddean@chori.org
Berna Atik, MD, MPH
Center for Immunobiology and Vaccine Development
Children's Hospital Oakland Research Institute
Oakland, Calif
Ton Thi Kim Thanh, MD;
Vu Quoc Luong, MD, PhD
National Institute of Ophthalmology
Ministry of Health
Stephan Lagree, PhD
Group Research in Technology Exchange
Hanoi, Vietnam
RELATED LETTERS
Targeted Treatment of Active Trachoma
David Mabey, Robin Bailey, Anthony Solomon, Matthew Burton, Clare Gilbert, Allen Foster, Thomas Lietman, and Sheila West
JAMA. 2007;297(6):588.
EXTRACT
| FULL TEXT
Targeted Treatment of Active Trachoma
Chandler R. Dawson and Julius Schachter
JAMA. 2007;297(6):588-589.
EXTRACT
| FULL TEXT
|
